Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31193361 | 1.00 | CNR2 (0.46) | CNR2CNR1THRATHRBMEN1 | |
| SCHEMBL31193427 | 0.92 | CNR1 (0.46) | CNR2CNR1THRATHRBMEN1 | |
| SCHEMBL2019737 | 0.92 | CNR1 (0.46) | CNR2CNR1THRATHRBMEN1 | |
| SCHEMBL13505329 | 0.85 | CNR1 (0.39) | CNR2CNR1THRATHRBMEN1 | |
| SCHEMBL2018327 | 0.82 | MAOB (0.45) | CNR2CNR1THRATHRBALDH1A1 | |
| SCHEMBL13837524 | 0.81 | CNR1 (0.43) | CNR2CNR1THRATHRBMEN1 | |
| SCHEMBL2016511 | 0.81 | NPC1 (0.42) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2020613 | 0.80 | S1PR2 (0.37) | — | |
| SCHEMBL533740 | 0.77 | MMP9 (0.38) | ALDH1A1TSHR | |
| SCHEMBL2018804 | 0.76 | ALDH1A1 (0.43) | CNR2CNR1THRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353147-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| US-9353148-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | claimed |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-27 | — | — | US | claimed |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | claimed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | claimed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | AJINOMOTO CO., INC. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| EP-3882255-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | AJINOMOTO CO., INC. (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-20210277063-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | AJINOMOTO CO., INC. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | CNR2 4682/4885CNR1 4670/4885THRA 2680/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | CNR2 4197/4885CNR1 4108/4885THRA 2016/4885 |
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | CNR2 2139/4885CNR1 2142/4885THRA 3778/4885 |
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | SPPL2B, PTMS, VIP | CNR2 4671/4885CNR1 4502/4885THRA 1246/4885 |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | VIP, ANPEP, NPPA | CNR2 4329/4885CNR1 4353/4885THRA 3003/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | CNR2 2710/4885CNR1 3237/4885THRA 3109/4885 |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | ANPEP, NPPA, LNPEP | CNR2 4129/4885CNR1 3645/4885THRA 2857/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | CNR2 4197/4885CNR1 4108/4885THRA 2016/4885 |
| US-20210277063-A1 | METHOD FOR PRODUCING CYCLIZED PEPTIDE HAVING INTRAMOLECULAR S-S BOND | SPPL2B, PTMS, VIP | CNR2 4671/4885CNR1 4502/4885THRA 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.